Novo Nordisk A/S, headquartered in Bagsvaerd, Denmark, is a dominant player in the GLP-1 receptor agonist market
Baseline micronutrient testing before starting, plus ongoing monitoring of nutrient status, is described as part of a sensible safety plan alongside hydration and electrolyte checks
Theyre created by pharmacies using the same active ingredient (semaglutide) as brand-name Ozempic and Wegovy, but they dont undergo the same rigorous testing and quality control processes that FDA-approved medications do
Tirzepatide, a dual GIP/GLP-1 receptor agonist approved by the FDA for diabetes management and chronic weight management, works by enhancing insulin secretion, suppressing glucagon, and reducing appetite
Originally developed for diabetes, semaglutide gained FDA approval for weight loss in 2021